Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) PEG Ratio

N/A

PE ratio relative to earnings growth — is the valuation justified?

—

PEG Ratio

Negative EPS growth — PEG not meaningful when earnings are declining

—

Current Price

$400.00

TTM EPS

$3.56

P/E Ratio

112.36

Growth Rate

-57.7%

3-Year EPS CAGR

Sector

Healthcare

Drug Manufacturers - General

Calculated

8/1/2026

2:19:50 PM

PEG Ratio Unavailable

Negative Growth — PEG not meaningful

Peer Comparison

Sample Size

6 peers

Industry Median PEG

1.41

25th Percentile

0.00

75th Percentile

1.52

Symbol	Company	PEG	P/E	Growth	vs BMYMP
ALPMY	Astellas Pharma Inc.	0.00	0.1	21.6%	—
ALPMF	Astellas Pharma Inc.	0.00	0.1	20.4%	—
AILLP	Ameren Illinois Company PFD 4%	1.30	11.4	8.8%	—
AZNCF	AstraZeneca PLC	1.51	31.0	20.5%	—
AILIM	Ameren Illinois Company	1.52	13.4	8.8%	—

How to Interpret PEG Ratio

PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.

PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."

PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.

Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) PEG Ratio

Peer Comparison

How to Interpret PEG Ratio

More on BMYMP

Compare with peers

Explore

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) PEG Ratio

Peer Comparison

How to Interpret PEG Ratio

More on BMYMP

Compare with peers

Explore